BeOne Medicines Ltd.ONC
BeOne Medicines Ltd. Financial Overview 2021–2025
Updated Jul 10, 2026BeOne Medicines orchestrated a structural financial inflection by converting a $1.4 billion net loss in FY2021 into a positive net income of $286.9 million in FY2025. This profitability cements the company’s transition from a cash-dependent biotech into a self-sustaining commercial oncology operator. The primary engine of this transformation is BRUKINSA, a BTK inhibitor that captured global market share to generate $3.9 billion in sales during FY2025.
The firm's operational execution has rapidly scaled its top line, with total revenue growing from $1.18 billion in FY2021 to $5.3 billion in FY2025. This expanding revenue base, up 40.2% year-over-year, now outpaces the company's clinical pipeline costs, even as research and development expenses climbed 9.9% to $2.1 billion in FY2025. Beyond its lead asset, the anti-PD-1 therapy TEVIMBRA provided secondary momentum with $737.3 million in annual sales, backed by a balance sheet holding $4.5 billion in liquidity at the close of FY2025.
Investors have priced in this commercial scaling and the clinical promise of next-generation assets like sonrotoclax. At the close of FY2025, the equity traded at $303.81 per share, commanding a $437.8 billion market capitalization. Because the company only recently crossed into positive earnings territory, it traded at a 1599.0x price-to-earnings multiple at the end of FY2025, reflecting steep market expectations for continued profit expansion.
Recent Developments (Q4 2025 and Q1 2026)
BeOne Medicines secured a major clinical milestone in May 2026 when the FDA granted accelerated approval to BEQALZI for relapsed or refractory mantle cell lymphoma. This first-in-class BCL2 approval compounds the firm’s operational momentum from Q1 2026, where total revenue hit $1.51 billion, a 35.5% year-over-year increase. BRUKINSA sales climbed 38.3% to $1.09 billion during the quarter, pushing operating income up 2,151.0% to $249.9 million and turning free cash flow positive at $160.5 million.
In June 2026, the company settled a statutory tax audit in China for $63.4 million, which will impact Q2 2026 results. Bulls argue that adding a second approved hematology asset to a rapidly expanding cash flow base justifies a premium valuation. Bears caution that trading at a 1649.1x price-to-earnings multiple as of May 6, 2026, the equity is priced for perfection and highly vulnerable to any commercial deceleration.
What to watch: initial BEQALZI launch trajectory and prescription volume; the absorption of the $63.4 million tax charge in Q2 2026 margins.
Rev
$5.34B
FY2025
NI
$286.9M
FY2025
EPS$ONC
$0.20
FY2025
OCF
$1.13B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
BeOne Medicines Ltd. 8-K Report, Corporate Update (Jun 26, 2026)
BeOne Medicines Ltd. (ONC) announced the conclusion of a statutory tax audit in China. Through a settlement with the local tax authority, the Company has agreed to an income tax payment of approximately RMB 446 million, which includes surcharges and related interest. Importantly, this settlement did not involve any administrative penalties. This payment is anticipated to be recognized in the Company's U.S. GAAP financial statements for the second quarter of fiscal year 2026. This event is a follow-up to previously disclosed ongoing tax audits in various international jurisdictions, which carry the risk of materially different liabilities than currently estimated.
BeOne Medicines Ltd. 8-K Report, Executive Changes (Jun 11, 2026)
BeOne Medicines Ltd. (ONC) held its Annual General Meeting on June 11, 2026, where key corporate governance and compensation matters were addressed. Notably, four directors, Michael Goller, Ranjeev Krishana, Dr. Corazon (Corsee) D. Sanders, and Qingqing Yi, did not seek re-election, and their terms concluded without disagreement. Shareholders overwhelmingly approved amendments to the Company's 2016 Share Option and Incentive Plan and the 2018 Employee Share Purchase Plan, significantly increasing the number of shares available for issuance under both. The company also received shareholder approval for its 2025 financial statements and the appropriation of accumulated losses. Significant votes of confidence were also cast for the re-election of existing directors and the election of new board members, including a new Compensation Committee member and the re-election of the Chairman of the Board. The appointment of Ernst & Young LLP as independent auditors for fiscal year 2026 was ratified.
BeOne Medicines Ltd. 8-K Report, Corporate Update (May 15, 2026)
BeOne Medicines Ltd. (ONC) has achieved a significant milestone with the U.S. Food and Drug Administration's (FDA) accelerated approval of BEQALZI™ (sonrotoclax). This approval is for adult patients suffering from relapsed or refractory mantle cell lymphoma (MCL) who have undergone at least two prior lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor. This represents a crucial advancement in treating a challenging form of lymphoma, positioning BEQALZI™ as a potentially vital new therapeutic option for a specific patient population. The accelerated approval pathway indicates that the FDA has recognized the drug's potential to address an unmet medical need. Investors should monitor the commercialization strategy and market uptake of BEQALZI™, as this approval is expected to be a key driver of future revenue growth for BeOne Medicines. Further details regarding the approval and its implications are provided in the press release filed as an exhibit.
BeOne Medicines Ltd. 8-K Report, Financial Results (May 6, 2026)
BeOne Medicines Ltd. (ONC) has filed an 8-K report on May 6, 2026, to announce its financial results for the first quarter ended March 31, 2026. The report primarily consists of a press release detailing these results and providing business updates. Investors should review the attached press release (Exhibit 99.1) for specific financial performance metrics and strategic developments during the quarter. While the 8-K filing itself is brief, referencing the press release is crucial. This filing serves as the official notification of ONC's Q1 2026 performance and any significant operational news. Investors are advised to consult the press release for details on revenue, expenses, net income/loss, cash flow, and any forward-looking statements or guidance provided by the company.
BeOne Medicines Ltd. 8-K Report, Financial Results (Apr 14, 2026)
BeOne Medicines Ltd. (ONC) has filed its 2025 Annual Report with the Shanghai Stock Exchange's STAR Market, adhering to PRC accounting standards. This report, presented in Chinese, includes financial information for the year ended December 31, 2025, prepared in accordance with China Accounting Standards for Business Enterprises (CAS) and other PRC GAAP. Importantly, for U.S. investors, the Company has furnished supplementary financial information as an exhibit to this 8-K filing. This exhibit provides key metrics such as gross profit margin, R&D expenses broken down by product and project, and production/sales/inventory data for 2025, all prepared under U.S. GAAP. It also details the material differences between PRC GAAP and U.S. GAAP. This filing serves as a crucial update for investors, bridging the information gap between the primary Chinese filing and U.S. reporting requirements. Investors should pay close attention to Exhibit 99.1, which offers a U.S. GAAP perspective on the company's financial performance and operational metrics. The availability of this U.S. GAAP reconciled data is vital for a comprehensive understanding of BeOne Medicines' financial health and operational status for the 2025 fiscal year.
View all 8-K filings →